Close menu




July 16th, 2026 | 07:15 CEST

Everyone Has to Pay—Why Investors Could Profit: The Toll Secret of InterDigital and AbbVie, Plus Globex Mining's Portfolio of 272 Resource Projects

  • royalties
  • Commodities
  • Digitization
  • patents
Photo credits: AI

The global economy is like a jungle, with toll booths waiting at every turn—anyone who wants to pass has to pay. A recent example is the rebranding of Siemens Energy to Omterra: even after being spun off from the Siemens Group, the company still has to pay for the right to use its former parent company's name. This toll-booth business model exists across many industries. Companies that own assets, technologies, or rights that others need can generate highly profitable, recurring revenue streams. We take a closer look at three compelling business models and highlight investment opportunities that could prove especially rewarding during periods of economic and technological transformation.

time to read: 3 minutes | Author: Nico Popp
ISIN: GLOBEX MINING ENTPRS INC. | CA3799005093 | TSX: GMX. OTCQX: GLBXF , ABBVIE INC. DL-_01 | US00287Y1091 , INTERDIGITAL (PA.) DL-_01 | US45867G1013

Table of contents:


    InterDigital: Patent Battles and Big Profits from Standard Licenses

    Anyone who uses a cell phone or streams videos today inevitably makes use of InterDigital's intellectual property. The US company has radically done away with its own manufacturing facilities. Instead, since the turn of the millennium, over USD 1.3 billion has been invested in the development of well over 30,000 patents and patent applications, 90% of which were developed in-house. This massive library of intellectual property rights becomes a toll booth as soon as international bodies adopt the technologies into binding mobile communications or video standards. Since there are no technical alternatives for hardware companies, the revenue, in the form of a mix of fixed-price agreements and unit-based licensing fees, flows in almost effortlessly.

    But InterDigital's business model is not a sure thing. Defending these toll booths requires constant legal readiness and comes with associated costs. The decades-long legal dispute with Lenovo shows that negotiations are often protracted. Only after countless court proceedings did the parties agree in October 2024 to a binding arbitration process. In Europe, too, InterDigital is dependent on litigation. The landmark decision by the European Court of Justice in February 2025 in the case of BSH Hausgeräte v. Electrolux allows patent holders, under certain conditions, to enforce non-EU intellectual property rights in European courts. This provides InterDigital with additional options. By licensing into the growing market for electric vehicle charging stations, the company is successfully expanding into new areas. Those who do not find legal disputes paralyzing may want to take a closer look at InterDigital's business model.

    AbbVie as a Biotechnology Powerhouse

    When it comes to innovative drugs and active ingredients, AbbVie masters the game of intellectual property rights and licensing like few other players. To cushion the risk of expiring active ingredient patents for Humira, once a billion-dollar cash cow, the US corporation erected an unprecedented thicket of patents consisting of nearly 250 patent applications. This protective barrier covered every conceivable modification, from the pain-reduced formulation to the sophisticated autoinjector pen, and successfully blocked biosimilar competitors from entering the US market until early 2023. Thanks to the window of opportunity this created, AbbVie was able to launch its successor drugs, Skyrizi and Rinvoq. The success of this move is evident in the raw numbers. The combined sales volume of these two new promising products reached the USD 25.87 billion mark in 2025.

    Globex Mining holds 272 mineral projects and occupies the bottleneck of the future

    While technology and pharmaceutical giants secure their toll booths with patents, Globex Mining is focusing on the mineral sector. Under the leadership of experienced geologist Jack Stoch, the company has, over decades, positioned itself as a diversified project and license generator. Instead of pouring hundreds of millions into the capital-intensive construction of a mine, Globex countercyclically secures promising mineral properties. With minimal investment of its own in historical data and surface sampling, the group further develops the projects before transferring them to financially strong partners in exchange for cash payments, share packages, and royalties.

    Globex Mining: Commodity properties as a core investment.

    The latest transactions by this innovative resource conglomerate prove that this model works. In June 2025, Agnico Eagle Mines paid the final tranche of CAD 3.0 million from the Francoeur sale, while Electro Metals will pay an additional CAD 3.5 million over four years for the Magusi-Fab deposit. With a well-stocked cash reserve of over CAD 40 million, no debt, and a portfolio totaling 272 resource assets, the license specialist is perfectly positioned in the current market environment. Several advanced license projects are set to come online by 2028, including the Bell Mountain gold project in Nevada and the Mont-Sorcier iron ore project in Quebec, which, according to a preliminary economic assessment, could generate annual GMR royalties of CAD 7 to 10 million for Globex.

    Bright Outlook for Globex: Geopolitical Tensions and a Defence Industry Renaissance

    Figures from independent experts confirm that Globex is well-positioned. The International Energy Agency (IEA) warns of an unprecedented supply gap for critical metals. To achieve net-zero targets by 2040, global demand for critical minerals must quadruple. While electric vehicles consume enormous amounts of copper and lithium, global exploration spending, adjusted for inflation, remains at a meagre 2% increase. Analysts estimate that the capital needed in the short term to develop new mining projects by 2030 alone amounts to an astronomical USD 250 to 350 billion, as drastic supply shortages otherwise loom. Globex has projects in North America for nearly all relevant commodities in its portfolio. This focus is unique. Thanks to consistent revenue from option agreements, Globex has not had to conduct a single share consolidation since 1987 and consistently limits dilution for shareholders. As a result, the company offers many of the qualities that long-term investors seek.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST

    BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk

    • Biotechnology
    • Biotech
    • Pharma
    • biosimilars
    • patents

    The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.

    Read

    Commented by Tarik Dede on October 9th, 2026 | 09:10 CEST

    Drones, AI and Gold: Samsung, Volatus Aerospace and Equinox Gold in Focus

    • Drones
    • Defense
    • geopolitics
    • AI
    • Gold
    • Commodities

    These are turbulent times for the stock markets. Interest rates are rising, bank stocks are weakening, and the number of mega-IPOs, including SpaceX and Anthropic, keeps growing. Parallels with previous stock-market crashes are becoming increasingly apparent. Yet many investors are still riding a wave of euphoria. The current bull market is already the longest in US stock-market history, driven largely by artificial intelligence. But the downside is becoming increasingly evident: valuations are high, and concentration in the major stock indices is enormous. Consider just one example: ten stocks, the so-called Magnificent Seven, along with Broadcom, AMD, and Micron, now account for 42% of the S&P 500. At these levels, there is little room for anything to go wrong. Even in this market environment, however, opportunities and risks coexist. Today, we take a closer look at Samsung, Volatus Aerospace and Equinox Gold.

    Read

    Commented by Matthias Schomber on October 9th, 2026 | 07:15 CEST

    Defense and Auto Stocks Stumble: Mercedes-Benz and Renk Seek Support as Lahontan Gold Sparks Imagination!

    • Gold
    • Silver
    • Commodities
    • Autonomous
    • Defense

    Should investors be seriously concerned about the performance of the flagship industries right now? The share price action of recent weeks certainly speaks volumes. As dark clouds gather over Stuttgart's automotive industry and even Hollywood stars can barely slow the decline, the once-booming defense sector is suddenly facing unexpected headwinds as well. Yet every volatile market also creates opportunities, often away from the mainstream. Today, we take a closer look at three companies that could be interesting now, or in the future, each in their own way. We start by examining the crisis-stricken automotive assembly lines at Mercedes-Benz, then turn to Renk, where defense margins could become a decisive factor. Finally, we head to usually sunny Nevada to examine a promising resource company that could make waves in the future. Read on! This stock analysis provides interesting facts and highlights potential investment opportunities that could be worth considering for your portfolio.

    Read